Quantcast
 
New book by Larry Connors Click here Improve your trading - See how


 

Form 4 Oracle: Boston, MA -- Form4Oracle: Insider Trading Report: Noven Pharmaceuticals Inc (NOVN)

Wed. November 26, 2008; Posted: 07:14 AM
Stocks RSS
Nov 26, 2008 (M2 PRESSWIRE via COMTEX) -- NOVN | Quote | Chart | News | PowerRating -- Price Michael Dennis, VP and Chief Financial Officer at Noven Pharmaceuticals Inc (NOVN) has reported buying $93.81K today.This purchase has increased overall holdings of Price Michael Dennis, VP and Chief Financial Officer in Noven Pharmaceuticals Inc by 67%.For a current, real-time summary of NOVN insider activity, visit http://www.form4oracle.com/company?cik=0000815838&ticker=NOVN

About Form4Oracle

Form4Oracle, LLC specializes in distributing insider trading information published by the SEC, making it accessible and actionable for all types of investors. To learn more about how tracking insider trading activity can improve your investment returns, visit http://www.form4oracle.com.

About Noven Pharmaceuticals Inc

Noven Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of prescription transdermal products and transdermal drug delivery technologies. It operates through two segments, Noven Transdermals and Noven Therapeutics. The Noven Transdermals segment?s products include Daytrana, a transdermal patch for the treatment of attention deficit hyperactivity disorder; Vivelle-Dot, a prescribed transdermal estrogen therapy product in the United States, as well as marketed primarily under the Estradot brand name outside the United States; CombiPatch, a combination estrogen/progestin transdermal patch marketed under the Estalis brand name outside the United States; Amphetamine Patch, a phase 1 clinical trial product for attention deficit hyperactivity disorder; and HSDD Patch for hypoactive sexual desire disorders. The Noven Therapeutics segment?s products comprise Pexeva for depressive disorder, panic disorder, obsessive compulsive disorder, and generalized anxiety disorder; Lithobid for bipolar disorder and related manic episodes; Stavzor for bipolar disorder, migraine therapy, and epilepsy; Stavzor ER, a pre-clinical trial product for bipolar disorder, migraine therapy, and epilepsy; Lithium QD for bipolar disorder and related manic episodes; Mesafem for vasomotor symptoms; and DentiPatch for dental pain associated with certain dental procedures. Noven Pharmaceuticals markets its products in the United States, Canada, and Japan, as well as in Europe. It has collaboration with Procter & Gamble Pharmaceuticals, Inc. for the development of new prescription patches for hypoactive sexual desire disorder. The company was founded in 1987 and is headquartered in Miami, Florida.

--------------------------------------------

The companies referenced in this report have not approved the statements made in this report. This report contains statements that imply risks and uncertainties. This material is for informational reporting purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Form4Oracle is not a licensed broker, broker dealer, market maker, investment banker, investment adviser, analyst or underwriter and is not compensated in this regard.

Please consult your broker to understand investing benefits and risks and prior to purchasing any securities mentioned herein.

CONTACT: Kimberly Sutton, Form4Oracle Tel: +1 312 315 5077 e-mail: kimberly@form4oracle.com WWW: http://www.form4oracle.com

M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

For full details on Noven Pharmaceuticals (NOVN) click here. Noven Pharmaceuticals (NOVN) has Short Term PowerRatings of 10. Details on Noven Pharmaceuticals (NOVN) Short Term PowerRatings is available at This Link.

    


More News:   Market Updates | Stock Alerts | All Trading News | Stock Index

Email
Print
Archives
Feedback
Email Article Link
Close X
Recipients email address
Your name
Your email
Add a note (optional)




Stocks RSS





Most Popular News
PREMIER SPONSORED LINKS
TRADE CENTER
 
The TradingMarkets Directory
RELATED SITES
Nothing but forex
Please call 1-213-955-5858 ext. 1

About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback

Disclaimer:

The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.

It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.

HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.

The Connors Group, Inc.
15260 Ventura Blvd., Ste. 2200
Sherman Oaks, CA 91403

© Copyright 2009 The Connors Group, Inc.


All analyst commentary provided on TradingMarkets.com is provided for educational purposes only. The analysts and employees or affiliates of TradingMarkets.com may hold positions in the stocks or industries discussed here. This information is NOT a recommendation or solicitation to buy or sell any securities. Your use of this and all information contained on TradingMarkets.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy.

© 2009 The Connors Group, Inc.